Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

Inclusion criteria: * Adult RRMS patients who will be initiating treatment with Lemtrada according to local approved label. * Signed written informed consent. Exclusion criteria: * Previously treated with LEMTRADA. * Contraindications to LEMTRADA according to the labeling in the country. * Any known contraindications to the symptomatic therapy used in the infusion management guidance based on their local approved label. * Currently participating in another investigational interventional study. * Any technical/administrative reason that makes it impossible to enroll the patient in the study. * Patient is the Investigator or any Sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol. * Patient who has withdrawn consent before enrollment (starting from signed informed consent form). * Despite screening of the patient, enrolment is stopped at the study level. * Woman of childbearing potential not protected by highly-effective method(s) of birth control (as defined in a local protocol amendment in case of specific local requirement) and/or who are unwilling or unable to be tested for pregnancy. * Pregnancy (defined as positive beta human chorionic gonadotropin (β-HCG) blood test), breast feeding. * Known infection with latent tuberculosis or active tuberculosis. * Known infection with Hepatitis B, Hepatitis C. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.